The SPDR S&P Biotech ETF (XBI) has seen a significant inflow of approximately $281.9 million, marking a 3.4% increase in outstanding units from 61,725,000 to 63,800,000 week over week. This change was reported today.
In trading, key components of XBI include Apellis Pharmaceuticals Inc (APLS), down 0.1%; TG Therapeutics Inc (TGTX), down 2.8%; and Travere Therapeutics Inc (TVTX), which is down 1.7%. XBI’s current share price stands at $135.05, with a 52-week low of $75.71 and a high of $139.19.
The ETF’s price performance relative to its 200-day moving average can provide valuable insights for investors looking to gauge its market trends.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
